Aastrom Biosciences, Inc. (ASTM) shares jumped Friday after the company announced that results from its Phase 2a clinical studies of ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy [DCM] showed that treatment with ixmyelocel-T reduced the incidence of major adverse cardiovascular events (MACE) in patients with ischemic DCM. “Based upon […] View the full post at: Aastrom Biosciences (ASTM) Shares Surge on Positive Treatment Results Related posts: Atlas Pipeline (APL) Shares Soar On Nat Gas Asset Sale Caterpillar Inc. Downgraded to “Neutral” at BofA